Immunocore Holdings PLC Sponsored ADR $IMCR Shares Purchased by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Immunocore Holdings PLC by 5.2%, acquiring an additional 351,610 shares, which now represents approximately 14.08% of the company valued at $209.2 million.
• Analysts have mixed ratings on Immunocore, with six analysts rating it a "Buy", while others have issued "Hold" and "Sell" ratings, indicating a consensus rating of "Moderate Buy" and an average price target of $58.00.
• Immunocore reported a revenue increase of 30% year-over-year for the last quarter, surpassing analyst expectations, with a reported revenue of $130.65 million.

T. Rowe Price Investment Management Inc. boosted its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 5.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,051,818 shares of the company's stock after purchasing an additional 351,610 shares during the period. T. Rowe Price Investment Management Inc. owned about 14.08% of Immunocore worth $209,228,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Primecap Management Co. CA lifted its position in Immunocore by 0.4% in the 1st quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company's stock valued at $79,476,000 after purchasing an additional 10,100 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Immunocore by 1.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after buying an additional 29,832 shares during the last quarter. Tang Capital Management LLC boosted its holdings in Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares in the last quarter. Fiera Capital Corp boosted its position in Immunocore by 3.2% in the first quarter. Fiera Capital Corp now owns 805,150 shares of the company's stock valued at $23,889,000 after buying an additional 25,186 shares in the last quarter. Finally, Deep Track Capital LP acquired a new position in Immunocore during the 4th quarter worth about $15,322,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on IMCR shares. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a research note on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target on the stock. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Oppenheimer boosted their price target on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $58.00.

Immunocore Stock Up 0.8%

Shares of IMCR traded up $0.26 during midday trading on Friday, hitting $32.93. 289,496 shares of the company's stock traded hands, compared to its average volume of 328,243. The firm's fifty day moving average is $33.30 and its 200-day moving average is $31.28. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -82.33 and a beta of 0.77. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $23.15 and a 1 year high of $39.33. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The company had revenue of $130.65 million during the quarter, compared to analysts' expectations of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm's revenue for the quarter was up 30.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.23) earnings per share. As a group, sell-side analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.